July 27, 2016 07:17 AM EDT

After a tough haul, John Lechleiter is stepping down at Eli Lilly

John Carroll

Editor & Founder

After steering Eli Lilly through a long R&D drought that leaves the pharma giant with some blockbuster drug prospects, Eli Lilly CEO John Lechleiter …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After a tough haul, John Lechleiter is stepping down at Eli Lilly

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Novo declares Phase 3 cardiac outcomes trial win for oral GLP-1

Starboard takes activist stake in J&J consumer spinout Kenvue

Former Karuna crew quickly assembles $225M for next neuro bet at Seaport

Q3 biotech roundup: The 2024 turnaround sputters into a critical Q4 finale

AstraZeneca-backed CDMO Nucleus RadioPharma to boost commercial capacity

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Af­ter a tough haul, John Lech­leit­er is step­ping down at Eli Lil­ly

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

After a tough haul, John Lechleiter is stepping down at Eli Lilly